David Simpson
Impact in
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 36
- Chronic Lymphocytic Leukemia Research 36
-
- Lymphoma Diagnosis and Treatment 19
- Co-authors
- Samar Issa (9 shared papers)Patrick Wood (9 shared papers)David A. Macdonald (7 shared papers)John M. Burke (7 shared papers)Kathryn S. Kolibaba (7 shared papers)Ian W. Flinn (8 shared papers)Brad S. Kahl (6 shared papers)Richard van der Jagt (4 shared papers)
- Journals
- Blood (29 papers)Hematological Oncology (6 papers)Haematologica (4 papers)British Journal of Haematology (4 papers)The Lancet Oncology (3 papers)
- Partner nations
- United StatesNew ZealandAustralia
In The Last Decade
David Simpson
77 papers receiving 7.5k citations
David Simpson's Hit Papers
Peers
Comparison fields: 5 of 93
- Genetics 2.6k
- Pathology and Forensic Medicine 2.1k
- Hematology 1.4k
- Oncology 1.2k
- Rheumatology 362
Countries citing papers authored by David Simpson
This map shows the geographic impact of David Simpson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Simpson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Simpson more than expected).
Fields of papers citing papers by David Simpson
This network shows the impact of papers produced by David Simpson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Simpson. The network helps show where David Simpson may publish in the future.
Co-authors
The 25 scholars most cited alongside David Simpson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 77 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Hit paper breakdown → | 2015 | 1301 |
| 2 | Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Hit paper breakdown → | 2010 | 844 |
| 3 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Hit paper breakdown → | 2019 | 521 |
| 4 | Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Hit paper breakdown → | 2014 | 517 |
| 5 | 2017 | 448 | |
| 6 | Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study Hit paper breakdown → | 2019 | 387 |
| 7 | 2014 | 363 | |
| 8 | Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL Hit paper breakdown → | 2019 | 303 |
| 9 | 2018 | 299 | |
| 10 | 2016 | 229 | |
| 11 | 2019 | 228 | |
| 12 | 2017 | 226 | |
| 13 | 2019 | 221 | |
| 14 | 2019 | 216 | |
| 15 | 2019 | 211 | |
| 16 | 2018 | 123 | |
| 17 | 2020 | 95 | |
| 18 | 2020 | 95 | |
| 19 | 2021 | 86 | |
| 20 | 2018 | 82 |
About David Simpson
David Simpson is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Oncology and Transplantation, having authored 77 papers that have together received 7.7k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (36 papers), Lymphoma Diagnosis and Treatment (19 papers), Multiple Myeloma Research and Treatments (9 papers), Viral-associated cancers and disorders (7 papers), Hematopoietic Stem Cell Transplantation (3 papers), Chronic Myeloid Leukemia Treatments (3 papers), Renal Transplantation Outcomes and Treatments (1 paper) and T-cell and B-cell Immunology (1 paper). The work is most often cited by research in Genetics (2.6k citations), Pathology and Forensic Medicine (2.1k citations), Hematology (1.4k citations), Oncology (1.2k citations) and Rheumatology (362 citations). David Simpson has collaborated with scholars based in United States, New Zealand and Australia. Frequent co-authors include Samar Issa, Patrick Wood, David A. Macdonald, John M. Burke, Kathryn S. Kolibaba, Ian W. Flinn, Brad S. Kahl, Richard van der Jagt, Doreen M. Hallman and Judith Trotman. Their work appears in journals such as Blood, Hematological Oncology, Haematologica, British Journal of Haematology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.